TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03833921: Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

Sponsor: Martha Mims · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 130 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT03833921 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03833921 Rescue Dossier →